Precision medicine is an emerging field in medicine for disease prevention and treatment that takes into account the individual variability in genes, environment, and lifestyle for each individual patient. The authors have developed a special program as part of the Englander Institute for Precision Medicine to grow patient-derived, 3-dimensional tumor organoids for tumor-specific drug testing, tailoring treatment strategies, and as models for studying drug resistance. Routine cytology preparations represent a cost-effective and powerful tool to aid in performing molecular testing in the age of personalized medicine. In this commentary, the platforms used for the characterization and validation of patient-derived, 3-dimensional tumor organoids are outlined and discussed, and the role of cytology as a cost-effective and powerful quality-control measure is illustrated.
INTRODUCTION
Precision oncology is a therapeutic approach, and its objective is to tailor treatment strategies for various types of malignancies based on the individual genetic profile of each patient's cancer. 1 This approach uses molecular information from the individual's cancer to determine diagnosis and prognosis. At the Englander Institute for Precision Medicine at Weill Cornell Medicine and New York-Presbyterian Hospital, we established a clinical program for whole-exome sequencing and development of patient-derived, 3-dimensional (3D) tumor organoids to be used for functional studies, such as pharmacologic screenings and drug resistance in tumors. 2, 3 3D in vitro models have been used in cancer research as an intermediate model between in vitro cancer cell line cultures and xenografts. [4] [5] [6] One of the limiting factors in growing primary tumor samples is the overgrowth and contamination of these samples by benign cells from adjoining tissues and the tumor microenvironment. To detect such contamination and to monitor tumor cell enrichment for patient-derived primary cultures, cytology appears to play a crucial role.
3D TUMOR ORGANOIDS
Over the past few decades, we have learned that cell-line models do not recapitulate the exact genetic make-up and tumor microenvironment of individual tumors and thus, greatly limit preclinical evaluation of newly targeted therapeutic agents. 7, 8 Furthermore, high failure rates have been attributed in part to the use of 2-dimensional (2D) monolayer cultures for drug screening and resistance studies, which tend to produce inaccurate results, and thus fail to predict chemoresistance. 9 These limitations can be reduced by the use of 3D-cultured tumor cells derived from individual patient's tumors to recapitulate a tumor-like microenvironment.
10
3D cell cultures create an environment in which the cells can grow and interact with their surroundings in all 3 dimensions, more accurately imitating the in vivo tumor environment compared with monolayer cells grown on plastic.
10 At the Englander Institute for Precision Medicine, we grow patient-derived, 3D tumor organoids for pharmacologic testing (Fig. 1 
PLATFORMS USED FOR THE CHARACTERIZATION AND VALIDATION OF PATIENT-DERIVED, 3D TUMOR ORGANOIDS

Cytology Smears
We evaluate smear preparations from the 3D cultures as the initial screening platform. Smears from the 3D cultures are prepared and screened to ensure that tumor cells are sampled from the cultures and not only from contaminants such as benign epithelial cells or fibroblasts.
In the initial step to help differentiate between tumor growth and contaminant growth, we use the gross morphology of the tumor organoids as a guide. The gross morphology of the 3D cultures tend to vary between samples (intersample variation) and also within a single sample (intrasample variation). Intrasample variation has been noted frequently in samples that exhibit the growth of both tumor organoids and benign cells (Fig. 3) .
Once a gross assessment of the 3D culture is made, up to 5 (morphology matched) individual organoids are collected using an Eppendorf Pipette under an inverted microscope and expelled onto a Super Frost Plus glass slide (Fisherbrand; Fisher Scientific/Thermo Fisher Scientific). A second slide is used as a spreader by placing it gently on top of the sample slide, either at a right angle or parallel to the sample slide. The top slide is then gently pulled across the sample (bottom) slide to thinly smear the sample. Airdried smears are then stained with a Diff-Quik stain (Siemens Medical Solutions USA, Inc, Malvren Pa). The stained smears are then reviewed by a board-certified cytopathologist (Fig. 4) . Only the organoids that contain tumor cells are individually harvested, further grown, and undergo molecular characterization according to the Precision Medicine Platform Standard Operation Procedures.
Histology
Formalin-fixed, paraffin-embedded (FFPE) tissue samples traditionally have been used for ancillary testing, such as immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH). Similarly, we use FFPE samples prepared from the tumor organoids (cell blocks) for further ancillary testing and for other testing modalities to help characterize the tumor organoids.
We use a specific protocol to prepare cell blocks on grossly identifiable tumor organoids with an average greatest dimension of approximately 500 to 800 lM. Fresh tumor organoids are enzymatically dissolved (Dispase; Sigma-Aldrich Corporation, St. Louis, Mo) out of the Matrigel and mixed with fibrinogen and thrombin (dilution. 1:10 volume/volume fibrinogen; Sigma-Aldrich Corporation) to form a clot before fixation with 4% paraformaldehyde, pH 7.4, in phosphatebuffered saline (PBS) (Affymetrix Inc, Santa Clara, Calif) and embedding in paraffin. Smaller tumor organoids that measure <500 lM in greatest dimension are initially fixed within the Matrigel scaffold in 4% paraformaldehyde, pH 7.4, in PBS and then embedded in paraffin. These FFPE blocks are then used for routine histology and for ancillary testing, such as IHC and/or FISH (Fig. 5) . 
Immunofluorescence
We use direct immunofluorescence staining to observe a specific protein or antigen in our tumor organoids by binding a specific antibody that is chemically conjugated with a fluorescent dye. Tumor organoids are dissolved out of the Matrigel (Corning Inc) and fixed in 4% paraformaldehyde, pH 7.4, before permeabilization (PBS and 1% Triton X-100) and blocking (PBS, 1% bovine serum albumin, 3% normal goat serum, and 0.2% Triton X-100). Incubation with the primary antibodies against the desired antigens is performed according to the manufacturer's suggestion or our specified Standard Operation Procedures. After secondary antibody incubation, tumor organoids are then imaged in a chamber slide (Nalge Nunc International, Rochester, NY) using a confocal microscope (Zeiss LSM510) (Fig. 6 ).
Molecular Analysis
After cytologic characterization of the 3D cultures, only tumor organoids that are positive for cancer cells are further characterized using next-generation sequencing. Our platform either uses the EXaCT-1 assay (HISeq2500; Illumina, Inc, San Diego, Calif) for whole-exome sequencing (data not shown) or the Cancer Gene Mutation Panel-50 (Ion Torrent), which interrogates 50 cancer-related genes in solid tumors. Good concordance in genomic alterations (copy numbers and mutations), have been demonstrated between the individual native tumors and the corresponding tumor organoids (Table 1) .
Conclusion
Routine cytology smears can represent a cost-effective and powerful tool to aid molecular testing in the age of personalized medicine.
11 Cytopathology has become a very efficient and cost-effective screening tool to confirm tumor cell-rich 3D cultures. In our program, cytologic assessment has become an absolute requirement for the growth of tumor organoids to ensure good culture quality. Cell culture, molecular characterization, and tissue banking of benign epithelial cell or fibroblast cultures can cause unnecessary personnel and material expenses. In conclusion, we have developed a workflow with different platforms for the establishment and characterization of patient-derived tumor organoid cultures. Patient-derived cancer cultures represent a promising area in personalized medicine to test drug sensitivity or study the effects of drug resistance on tumors.
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